// App-Quantinova.ai

5545 : Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis.

Researchers

Presenter

  • Andres Poveda

Principal Investigators

  • Nicoletta Colombo

  • David Cibula

  • Kristina Lindemann

  • Johanne I Weberpals

  • Maria Bjurberg

  • Ana Oaknin

  • Magdalena Sikorska

  • Antonio Gonzalez Martin

  • Radoslaw Madry

  • Mara Jesus Rubio

  • Jonathan A. Ledermann

  • Richard Davidson

  • Christopher Blakeley

  • James Bennett

  • Jessica Brown

  • Alan Barnicle

  • Erik Skof

Medical Centers

  • Initia Oncology, Valencia, Spain

  • Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada

  • Istituto Europeo di Oncologia, Milano, Italy

  • First Faculty Medicine of the Charles University Hospital, Prague, Czech Republic, Oslo University Hospital, Oslo, Norway

  • Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

  • Lund University Hospital and Lund University, Lund, Sweden

  • Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus,Barcelona,Spanien

  • Olsztyn Provincial Specialist Hospital, Olsztyn, Poland

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Clinical Hospital of the Transfiguration of the Lord’s Medical University Karol Marcinkowski, Poznań, Poland

  • Department of Pathology, Hospital Universitario Reina Sofia, Cordoba, Spain

  • UCL Cancer Institute, University College London,, London, United Kingdom

  • Institute of Oncology Ljubljana, Ljubljana, Slovenia

Locations

  • Spain

  • Canada

  • Italy

  • Norway

  • Sweden

  • Poland

  • United Kingdom

  • Slovenia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Gynaecological cancer

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • BRCA mutation

Drug/Treatment

  • Olaparib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT00753545

  • NCT01874353

  • NCT03402841

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved